Portfolio auf einen Blick
Wertschriften per 30. September 2025
Gesellschaft | Anzahl Wert- schriften | Verände- rung seit 31.12.2024 | Währung | Aktienkurs | Kurswert in Mio. CHF | In % der Wert- schriften | In % des Eigen- kapitals | In % der Gesell- schaft | ||||||||
Ionis Pharmaceuticals | 6 224 838 | (1 625 162) | USD | 65.42 | 324.3 | 14.6% | 14.1% | 3.9% | ||||||||
Argenx SE | 535 322 | (55 678) | USD | 737.56 | 314.4 | 14.1% | 13.6% | 0.9% | ||||||||
Revolution Medicines | 5 567 000 | 1 192 700 | USD | 46.70 | 207.0 | 9.3% | 9.0% | 3.0% | ||||||||
Neurocrine Biosciences | 1 760 000 | (60 000) | USD | 140.38 | 196.8 | 8.8% | 8.5% | 1.8% | ||||||||
Alnylam Pharmaceuticals | 438 679 | (321 321) | USD | 456.00 | 159.3 | 7.1% | 6.9% | 0.3% | ||||||||
Vertex Pharmaceuticals | 457 800 | (17 200) | USD | 391.64 | 142.8 | 6.4% | 6.2% | 0.2% | ||||||||
Agios Pharmaceuticals | 3 714 736 | 199 586 | USD | 40.14 | 118.8 | 5.3% | 5.1% | 6.4% | ||||||||
Incyte | 1 435 855 | (714 145) | USD | 84.81 | 97.0 | 4.4% | 4.2% | 0.7% | ||||||||
Scholar Rock Holding | 3 237 377 | 750 670 | USD | 37.24 | 96.0 | 4.3% | 4.2% | 3.4% | ||||||||
Akero Therapeutics | 2 382 755 | 2 382 755 | USD | 47.48 | 90.1 | 4.0% | 3.9% | 3.0% | ||||||||
Immunocore | 2 796 803 | 1 591 339 | USD | 36.33 | 80.9 | 3.6% | 3.5% | 5.6% | ||||||||
Avidity Biosciences | 2 152 862 | 2 152 862 | USD | 43.57 | 74.7 | 3.4% | 3.2% | 1.6% | ||||||||
Celldex Therapeutics | 3 557 669 | 486 054 | USD | 25.87 | 73.3 | 3.3% | 3.2% | 5.4% | ||||||||
Beam Therapeutics | 2 889 288 | 1 371 167 | USD | 24.27 | 55.8 | 2.5% | 2.4% | 2.9% | ||||||||
Rivus Pharmaceuticals 1) | USD | 43.4 | 1.9% | 1.9% | ||||||||||||
Edgewise Therapeutics | 2 775 997 | 1 347 068 | USD | 16.22 | 35.9 | 1.6% | 1.6% | 2.6% | ||||||||
Relay Therapeutics | 8 343 318 | 968 318 | USD | 5.22 | 34.7 | 1.6% | 1.5% | 4.8% | ||||||||
Biohaven | 2 802 853 | 762 000 | USD | 15.01 | 33.5 | 1.5% | 1.5% | 2.6% | ||||||||
Wave Life Sciences | 4 094 458 | – | USD | 7.32 | 23.9 | 1.1% | 1.0% | 2.6% | ||||||||
Macrogenics | 9 919 992 | (9 971) | USD | 1.68 | 13.3 | 0.6% | 0.6% | 15.7% | ||||||||
Annexon | 5 157 290 | – | USD | 3.05 | 12.5 | 0.6% | 0.5% | 4.7% | ||||||||
Blueprint Medicines – Contingent Value Right | 284 900 | 284 900 | USD | 0.46 | 0.1 | 0.0% | 0.0% | |||||||||
Total Wertschriften | 2 228.5 | 100.0% | 96.6% | |||||||||||||
Übrige Aktiven | 82.2 | 3.6% | ||||||||||||||
Übrige Verbindlichkeiten | (3.7) | (0.2%) | ||||||||||||||
Innerer Wert | 2 307.1 | 100.0% | ||||||||||||||
1Nicht börsennotierte Gesellschaft
Wechselkurs per 30.09.2025: USD/CHF: 0.7964